Cargando…

Low-dose dexamethasone during arthroplasty: What do we know about the risks?

Dexamethasone is commonly applied during arthroplasty to control post-operative nausea and vomiting (PONV). However, conflicting views of orthopaedic surgeons and anaesthesiologists regarding the use of dexamethasone raise questions about risks of impaired wound healing and surgical site infections...

Descripción completa

Detalles Bibliográficos
Autores principales: Wegener, Jessica T., Kraal, Tim, Stevens, Markus F., Hollmann, Markus W., Kerkhoffs, Gino M.M.J., Haverkamp, Daniël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: British Editorial Society of Bone and Joint Surgery 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367537/
https://www.ncbi.nlm.nih.gov/pubmed/28461961
http://dx.doi.org/10.1302/2058-5241.1.000039
_version_ 1782517788961669120
author Wegener, Jessica T.
Kraal, Tim
Stevens, Markus F.
Hollmann, Markus W.
Kerkhoffs, Gino M.M.J.
Haverkamp, Daniël
author_facet Wegener, Jessica T.
Kraal, Tim
Stevens, Markus F.
Hollmann, Markus W.
Kerkhoffs, Gino M.M.J.
Haverkamp, Daniël
author_sort Wegener, Jessica T.
collection PubMed
description Dexamethasone is commonly applied during arthroplasty to control post-operative nausea and vomiting (PONV). However, conflicting views of orthopaedic surgeons and anaesthesiologists regarding the use of dexamethasone raise questions about risks of impaired wound healing and surgical site infections (SSI). The aim of this systematic review is to determine the level of evidence for the safety of a peri-operative single low dose of dexamethasone in hip and knee arthroplasty. We systematically reviewed literature in PubMed, EMBASE and Cochrane databases and cited references in articles found in the initial search from 1980 to 2013 based on predefined inclusion criteria. The review was completed with a ‘pro’ and ‘con’ discussion. After identifying 11 studies out of 104, only eight studies met the inclusion criteria. In total, 1335 patients were studied without any incidence of SSI. Causes of SSI are multifactorial. Therefore, 27 205 patients would be required (power = 90%, alpha = 0.05) to provide substantiated conclusions on safety of a single low dose of dexamethasone. Positively, many studies demonstrated showed convincing effects of low-dose dexamethasone on prevention of PONV and dose-dependent effects on post-operative pain and quality of recovery. Dexamethasone induces hyperglycaemia, but none of the studies demonstrated a concomitant SSI. Conversely, animal studies showed that high dose dexamethasone inhibits wound healing. A team approach of anaesthesiologists and orthopaedic surgeons is mandatory in order to balance the risk–benefit ratio of peri-operatively applied steroids for individual arthroplasty patients. We did not find evidence that a single low dose of dexamethasone contributes to SSI or wound healing impairment from the current studies. Cite this article: Wegener JT, Kraal T, Stevens MF, Hollman MW, Kerkhoffs GMMJ, Haverkamp D. Low-dose dexamethasone during arthroplasty: what do we know about the risks? EFORT Open Rev 2016;1:303-309. DOI: 10.1302/2058-5241.1.000039.
format Online
Article
Text
id pubmed-5367537
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher British Editorial Society of Bone and Joint Surgery
record_format MEDLINE/PubMed
spelling pubmed-53675372017-05-01 Low-dose dexamethasone during arthroplasty: What do we know about the risks? Wegener, Jessica T. Kraal, Tim Stevens, Markus F. Hollmann, Markus W. Kerkhoffs, Gino M.M.J. Haverkamp, Daniël EFORT Open Rev General Orthopaedics Dexamethasone is commonly applied during arthroplasty to control post-operative nausea and vomiting (PONV). However, conflicting views of orthopaedic surgeons and anaesthesiologists regarding the use of dexamethasone raise questions about risks of impaired wound healing and surgical site infections (SSI). The aim of this systematic review is to determine the level of evidence for the safety of a peri-operative single low dose of dexamethasone in hip and knee arthroplasty. We systematically reviewed literature in PubMed, EMBASE and Cochrane databases and cited references in articles found in the initial search from 1980 to 2013 based on predefined inclusion criteria. The review was completed with a ‘pro’ and ‘con’ discussion. After identifying 11 studies out of 104, only eight studies met the inclusion criteria. In total, 1335 patients were studied without any incidence of SSI. Causes of SSI are multifactorial. Therefore, 27 205 patients would be required (power = 90%, alpha = 0.05) to provide substantiated conclusions on safety of a single low dose of dexamethasone. Positively, many studies demonstrated showed convincing effects of low-dose dexamethasone on prevention of PONV and dose-dependent effects on post-operative pain and quality of recovery. Dexamethasone induces hyperglycaemia, but none of the studies demonstrated a concomitant SSI. Conversely, animal studies showed that high dose dexamethasone inhibits wound healing. A team approach of anaesthesiologists and orthopaedic surgeons is mandatory in order to balance the risk–benefit ratio of peri-operatively applied steroids for individual arthroplasty patients. We did not find evidence that a single low dose of dexamethasone contributes to SSI or wound healing impairment from the current studies. Cite this article: Wegener JT, Kraal T, Stevens MF, Hollman MW, Kerkhoffs GMMJ, Haverkamp D. Low-dose dexamethasone during arthroplasty: what do we know about the risks? EFORT Open Rev 2016;1:303-309. DOI: 10.1302/2058-5241.1.000039. British Editorial Society of Bone and Joint Surgery 2016-08-26 /pmc/articles/PMC5367537/ /pubmed/28461961 http://dx.doi.org/10.1302/2058-5241.1.000039 Text en © 2016 The author(s) https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) licence (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed.
spellingShingle General Orthopaedics
Wegener, Jessica T.
Kraal, Tim
Stevens, Markus F.
Hollmann, Markus W.
Kerkhoffs, Gino M.M.J.
Haverkamp, Daniël
Low-dose dexamethasone during arthroplasty: What do we know about the risks?
title Low-dose dexamethasone during arthroplasty: What do we know about the risks?
title_full Low-dose dexamethasone during arthroplasty: What do we know about the risks?
title_fullStr Low-dose dexamethasone during arthroplasty: What do we know about the risks?
title_full_unstemmed Low-dose dexamethasone during arthroplasty: What do we know about the risks?
title_short Low-dose dexamethasone during arthroplasty: What do we know about the risks?
title_sort low-dose dexamethasone during arthroplasty: what do we know about the risks?
topic General Orthopaedics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367537/
https://www.ncbi.nlm.nih.gov/pubmed/28461961
http://dx.doi.org/10.1302/2058-5241.1.000039
work_keys_str_mv AT wegenerjessicat lowdosedexamethasoneduringarthroplastywhatdoweknowabouttherisks
AT kraaltim lowdosedexamethasoneduringarthroplastywhatdoweknowabouttherisks
AT stevensmarkusf lowdosedexamethasoneduringarthroplastywhatdoweknowabouttherisks
AT hollmannmarkusw lowdosedexamethasoneduringarthroplastywhatdoweknowabouttherisks
AT kerkhoffsginommj lowdosedexamethasoneduringarthroplastywhatdoweknowabouttherisks
AT haverkampdaniel lowdosedexamethasoneduringarthroplastywhatdoweknowabouttherisks